Roche, Sanofi arthritis drugs reduce death rates among sickest COVID-19 patients

Treating critically ill COVID-19 patients with Roche’s Actemra or Sanofi’s Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday.